In a phase I study, 5-azacytidine (a DNMT inhibitor) and romidepsin (a HDAC inhibitor) were combined for the treatment of patients with peripheral T-cell lymphoma (PTCL) (148). Here, HDAC9 is linked to peripheral T-cell lymphoma, not otherwise specified.